Zacks Investment Research Lowers Oncolytics Biotech (NASDAQ:ONCY) to Hold

Zacks Investment Research downgraded shares of Oncolytics Biotech (NASDAQ:ONCY) from a buy rating to a hold rating in a report issued on Tuesday morning, reports.

According to Zacks, “Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated Ras pathway, one of the most common family of genetic defects leading to cancer. “

Separately, ValuEngine lowered Zumiez from a hold rating to a sell rating in a research note on Tuesday, July 2nd.

Shares of NASDAQ:ONCY opened at $1.61 on Tuesday. The company has a quick ratio of 3.39, a current ratio of 3.39 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $32.88 million, a PE ratio of -1.96 and a beta of 2.03. The company has a fifty day moving average of $1.74. Oncolytics Biotech has a fifty-two week low of $1.60 and a fifty-two week high of $5.74.

Oncolytics Biotech (NASDAQ:ONCY) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($0.21) EPS for the quarter. Equities research analysts forecast that Oncolytics Biotech will post -0.9 earnings per share for the current fiscal year.

About Oncolytics Biotech

Oncolytics Biotech Inc, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses.

See Also: Yield Curve

Get a free copy of the Zacks research report on Oncolytics Biotech (ONCY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit